Browse Studies About FAQ

Sign in Get started

Match. Apply. Get paid. The simplest way to participate in paid clinical research.

Product

Browse Studies How it Works Verification Arctuva Pro For Sponsors

Company

About Contact FAQ

Legal

Privacy Terms of Service Security Accessibility Transparency Report

© 2026 Arctuva, Inc. All rights reserved.

Compensation is for time and inconvenience, not income.

Browse Studies — Arctuva | Arctuva

Browse studies

Find your next paid study

1 recruiting study matching your filters

Newest first Highest paying

Filters

Condition

Location

Phase

Min compensation ($)

Max compensation ($)

Phase II Clinical Trial Evaluating the Safety Efficacy of Fc-Modified Anti-CD154 mAB (TNX-1500) in Kidney Transplant Recipients

The primary objective is to investigate the safety of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.

Kidney TransplantKidney Transplant Failure and RejectionImmunosuppression+1 more

~$10 – $7,500

Ayman Al Jurdi, MDNCT07204080